SHANGHAI SHEN LIAN BIOMEDICAL CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.9 CNY | +2.94% |
|
+11.36% | -34.49% |
| Feb. 28 | Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Shen Lian Biomedical Obtains Production License, GMP Certificate | MT |
| Sales 2021 | 358M 49.47M | Sales 2022 | 329M 45.35M | Capitalization | 3.26B 450M |
|---|---|---|---|---|---|
| Net income 2021 | 110M 15.18M | Net income 2022 | 61M 8.42M | EV / Sales 2021 | 11.3 x |
| Net cash position 2021 | 468M 64.56M | Net cash position 2022 | 357M 49.33M | EV / Sales 2022 | 8.83 x |
| P/E ratio 2021 |
40.9
x | P/E ratio 2022 |
52.9
x | Employees | 365 |
| Yield 2021 * |
-
| Yield 2022 |
1.01% | Free-Float | 38.4% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.94% | ||
| 1 week | +11.36% | ||
| Current month | -12.81% | ||
| 1 month | -12.97% | ||
| 3 months | -20.97% | ||
| 6 months | -28.15% | ||
| Current year | -34.49% |
1 week
4.52
4.92
1 month
4.395.86
Current year
4.187.58
1 year
4.188.13
3 years
4.1814.20
5 years
4.1836.88
10 years
4.1836.88
| Managers | Title | Age | Since |
|---|---|---|---|
Xu Gao
CEO | Chief Executive Officer | 53 | 06-12-31 |
Rui Ling Li
DFI | Director of Finance/CFO | 51 | 21-03-25 |
Dong Sheng Nie
CHM | Chairman | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shouchang Wu
BRD | Director/Board Member | 57 | - |
Shu Ching Lin
BRD | Director/Board Member | 56 | - |
James Chui
BRD | Director/Board Member | - | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 4.9 | +2.94% | 1,956,488 |
| 24-04-22 | 4.76 | +0.85% | 2,032,792 |
| 24-04-19 | 4.72 | -0.42% | 2,045,157 |
| 24-04-18 | 4.74 | -1.25% | 2,320,544 |
| 24-04-17 | 4.8 | +9.09% | 3,705,202 |
End-of-day quote Shanghai S.E., April 22, 2024
More quotes
Shanghai Shen Lian Biomedical Corp is a China-based company mainly engaged in the research, development, production and sales of veterinary biological products. The Company is committed to the research & development of foot and mouth disease vaccines, which are used to protect animals from foot and mouth diseases. The Company's main product are swine foot and mouth disease vaccines, and it also provides cattle foot and mouth disease vaccines, other swine vaccines, and other veterinary diagnostic reagents. The Company mainly sells its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.49% | 278M | |
| -24.22% | 68.34B | |
| +15.00% | 3.41B | |
| -0.14% | 3.21B | |
| +2.36% | 1.46B | |
| -14.76% | 1.38B | |
| -3.42% | 1.25B | |
| -27.49% | 1.21B | |
| -13.84% | 1.13B | |
| -1.95% | 1.03B |
- Stock Market
- Equities
- 688098 Stock
